AVREND

Serial Number 75774733
606

Registration Progress

Application Filed
Aug 13, 1999
Under Examination
Jul 4, 2000
Approved for Publication
Mar 10, 2000
Published for Opposition
Apr 11, 2000
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: AVREND
Previous Owner: Immunex Corporation
Classes: 005

Trademark Image

AVREND

Basic Information

Serial Number
75774733
Filing Date
August 13, 1999
Published for Opposition
April 11, 2000
Abandonment Date
January 5, 2002
Drawing Code
1000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 5, 2002
Classes
005

Rights Holder

Immunex Corporation

03
Address
51 University Street
Seattle, WA 98101

Ownership History

Immunex Corporation

Original Applicant
03
Seattle, WA

Immunex Corporation

Owner at Publication
03
Seattle, WA

Legal Representation

Attorney
Laurence R, Hefter

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

12 events
Date Code Type Description Documents
Feb 20, 2003 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jul 10, 2001 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jun 21, 2001 EXT2 S SOU EXTENSION 2 FILED Loading...
Feb 11, 2001 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 20, 2000 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 4, 2000 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 11, 2000 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 10, 2000 NPUB O NOTICE OF PUBLICATION Loading...
Jan 18, 2000 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 5, 2000 CNEA F EXAMINER'S AMENDMENT MAILED Loading...
Dec 9, 1999 CNRT F NON-FINAL ACTION MAILED Loading...
Nov 18, 1999 DOCK D ASSIGNED TO EXAMINER Loading...

Detailed Classifications

Class 005
Pharmaceuticals, namely, pharmaceutical for use in treating paraneoplastic and neoplastic diseases and cancer, pharmaceuticals for use as prophylaxis or treatment of infectious diseases, pharmaceuticals for use as adjuvant to vaccination, pharmaceuticals for use in activating or expanding cell populations in ex vivo settings or processes, pharmaceuticals for use in the treatment of immune diseases and immune deficiencies, and pharmaceuticals for use in treatment of bone diseases and disorders
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005